Evidence map›Paper›PMID 22689804›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2012

Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: a report from the Children's Oncology Group.

Stephan D Voss, Lu Chen, Louis S Constine, Allen Chauvenet, Thomas J Fitzgerald, Sue C Kaste, Thomas Slovis, Cindy L Schwartz

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00005578 (Advanced Stage Hodgkins Disease - A Pediatric Oncology Group Phase III Study), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00005578 phase3completednot on this map

Advanced Stage Hodgkins Disease - A Pediatric Oncology Group Phase III Study

TypeinterventionalSponsorChildren's Oncology GroupRan1997 to 2008Enrolled219ConditionsCardiac Toxicity, LymphomaArmsbleomycin sulfate, filgrastim, cyclophosphamide, dexrazoxane hydrochloride, doxorubicin hydrochloride
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. [Diagnostics (Basel, Switzerland) · 2023
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Bending the Cost Curve in Childhood Cancer.Current hematologic malignancy reports · 2016
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Surveillance imaging in pediatric Hodgkin Lymphoma.Current hematologic malignancy reports · 2013
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Stephan D VossBoston Children's Hospital, 300 Longwood Ave, Boston, MA 02420, USA. stephan.voss@childrens.harvard.edu
Lu Chen
Louis S Constine
Allen Chauvenet
Thomas J Fitzgerald
Sue C Kaste
Thomas Slovis
Cindy L Schwartz
Children's Hospital & Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PURPOSE Children with Hodgkin's lymphoma (HL) routinely undergo surveillance computed tomography (CT) imaging for up to 5 years after therapy, resulting in cost and radiation exposure, without clear benefit. The objective of this study was to determine the contribution of surveillance CT, as compared with clinical findings, to detection of disease recurrence. PATIENTS AND METHODS Two hundred sixteen patients, age ≤ 21 years old, were treated on the multicenter Pediatric Oncology Group 9425 trial. Data for patients who experienced relapse were retrospectively reviewed to determine whether imaging or clinical events prompted suspicion of disease recurrence. Correlation was made to disease stage, time to recurrence, relapse site, and overall survival (OS). Results With a median follow-up time of 7.4 years, 25 (11.6%) of 216 patients had experienced a relapse, of whom 23 experienced local relapse. Median time to relapse was 7.6 months (range, 0.2 to 48.9 months). Nineteen relapses (76%) were detected based on symptoms, laboratory or physical examination findings, and two relapses (8%) were detected by imaging within the first year after therapy. Only four patients (16%) had their recurrence detected exclusively by surveillance imaging after the first year. Six deaths occurred, all in patients who experienced relapse within the first year after therapy. No patient with a recurrence after 1 year off treatment has died, regardless of how the recurrence was detected. CONCLUSION The majority of pediatric HL relapses occurred within the first year after therapy or were detected based on change in clinical status. Detecting late relapse, whether by imaging or clinical change, did not affect OS. These findings indicate that CT is overused for routine surveillance of patients with HL.

Indexed as

Population SurveillanceTomography, X-Ray ComputedAdolescentChildChild, PreschoolFemaleFollow-Up StudiesHodgkin DiseaseHumansKaplan-Meier EstimateMagnetic Resonance ImagingMaleMultimodal ImagingNeoplasm StagingPositron-Emission TomographyPredictive Value of Tests

Identifiers

PMID22689804
PMCPMC4559601
OpenAlexW2127790520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.